Overview

Galantamine and CBT4CBT Pilot

Status:
Completed
Trial end date:
2019-02-28
Target enrollment:
Participant gender:
Summary
The investigators are proposing a randomized pilot feasibility study to evaluate the effects of galantamine versus placebo on preventing relapse to opioid use following tapering from methadone or buprenorphine maintenance (Medication Assisted Treatment, or MAT) among adults with opioid use disorder, with additional behavioral therapy (web-based cognitive behavioral therapy) provided across all conditions to help individuals successfully transition from MAT to a drug-free state.
Phase:
Early Phase 1
Details
Lead Sponsor:
Yale University
Collaborator:
National Institute on Drug Abuse (NIDA)
Treatments:
Galantamine